Anzeige
Mehr »
Login
Mittwoch, 23.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
KI-Energiekrise: Wie dieser Small Cap die nukleare Zukunft des Silicon Valley befeuern könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 881832 | ISIN: SE0000120669 | Ticker-Symbol: SKWC
Tradegate
23.10.24
08:00 Uhr
4,273 Euro
+0,015
+0,35 %
Branche
Eisen/Stahl
Aktienmarkt
STOXX Europe 600
1-Jahres-Chart
SSAB AB B Chart 1 Jahr
5-Tage-Chart
SSAB AB B 5-Tage-Chart
RealtimeGeldBriefZeit
4,2324,23514:16
4,2354,23614:17
GlobeNewswire (Europe)
49 Leser
Artikel bewerten:
(0)

SSAB AB: Interim report Q3 2024: Special Steels stable in a weak market, transformation on plan

The third quarter

  • Revenue was SEK 24,373 (29,339) million
  • Operating result was SEK 1,248 (4,371) million
  • Earnings per share were SEK 1.05 (3.40)
  • Net cash was SEK 13.3 (16.8) billion

    Comments by the CEO

    SSAB's operating result for the third quarter of 2024 amounted to SEK 1,248 (4,371) million. Maintenance cost amounted to SEK 950 million in the quarter, in line with forecast. Lower US plate prices impacted negatively compared to a year earlier. The market in Europe continued to be weak, whereas the market for high-strength steel was more resilient. Compared to the second quarter, the lower operating result was due to weaker demand and planned maintenance outages.

    SSAB Special Steels had an operating result of SEK 1,228 (1,808) million and an operating margin of 18% (23%) during the quarter. SSAB Special Steels' unique offering provides added value for our customers and this in turn translates into more stable prices than for standard products. SSAB Americas' operating result for the third quarter decreased to SEK 78 (2,653) million and the operating margin was 2% (35%), due to lower prices and planned maintenance outages. SSAB Europe's operating result was SEK 42 (254) million and the operating margin was 0% (2%).

    Safety performance continued to improve and LTIF decreased to 0.82 (0.94) during the quarter.

    The market in Europe was weak during the third quarter and the plate prices in the US weakened further. During the fourth quarter, SSAB will carry out planned maintenance in Oxelösund and Raahe. Further adjustments to the low demand will take place in the steel divisions within the framework for flexible working hours and a restrictive approach to costs. The market remains challenging also for Tibnor and Ruukki Construction, but earlier measures to reduce costs had a positive effect in the third quarter.

    The transformation to fossil-free steelmaking continues according to plan with a focus on the conversion of Oxelösund and the planning of the state-of-the-art, highly-effective mini-mill in Luleå. The new mill in Luleå will reduce production costs while increasing the share of premium products, strengthening SSAB's long-term competitiveness.

    The new direct reduction technology using hydrogen under development by HYBRIT is well positioned for an industrial scale, which lays the foundation for a flexible mix of fossil-free sponge iron and recycled scrap as raw material for the new mills in Oxelösund and Luleå in the long-term. The HYBRIT pilot plant in Luleå has to date produced more than 5,000 tonnes of hydrogen reduced iron and pilot volume of fossil-free steel is being used by several customers including Volvo Group, Epiroc and Peab.

    SSAB invites you to a presentation of the Q3 2024 report at 9.30am CEST on Wednesday, October 23, 2024.

    The report will be presented by SSAB's President and CEO Martin Lindqvist, and CFO Leena Craelius.

    The press conference will be held in English and live webcast on SSAB's website www.ssab.com.
    Link to webcast: https://edge.media-server.com/mmc/p/udknwkbc

    You can also participate in the briefing by telephone. Click on the link below and complete the online registration form. You can choose if you want to dial in or click "Call Me" for a call-back.
    Link to teleconference: https://register.vevent.com/register/BI96633f828f9b497cadadd79dffd41c0e

    For further information, please contact:
    Per Hillström, Head of Investor Relations, per.hillstrom@ssab.com, phone: +46 702 95 29 12
    Viktoria Karsberg, Head of Corporate Identity and Group Communications,
    viktoria.karsberg@ssab.com, phone: +46 72 233 5288

    This information is inside information that SSAB AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and information that SSAB AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7.30am CEST on October 23, 2024.

    SSAB is a Nordic and US-based steel company that builds a stronger, lighter and more sustainable world through value added steel products and services. Working with our partners, SSAB has developed SSAB Fossil-free steel and plans to reinvent the value chain from the mine to the end customer, largely eliminating carbon dioxide emissions from our own operations. SSAB Zero, a largely carbon emission-free steel based on recycled steel, further strengthens SSAB's leadership position and our comprehensive, sustainable offering independent of the raw material. SSAB has employees in over 50 countries and production facilities in Sweden, Finland and the US. SSAB is listed on Nasdaq Stockholm and has a secondary listing on Nasdaq Helsinki. Join us on our journey! www.ssab.com, Facebook, Instagram, LinkedIn, X and YouTube.


    © 2024 GlobeNewswire (Europe)
    Tenbagger-Chance mit der nächsten BioNTech

    Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

    Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

    Warum sollten Sie dabei sein?

    Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

    Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

    Verpassen Sie nicht diese Chance!

    Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

    Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

    Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.